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Material and Method: This work was carried out with MCNP 
and Geant4 codes. The 10x10x10 cm3 cubic water phantom 
and a tumor region with a size of 1x1x1 cm3 were simulated. 
Factors such as different concentrations and GNP sizes were 
implemented into the simulation, so as to obtain the 
optimum results, specifying the maximum absorbed dose 
within the tumor while sparing healthy tissue. In a certain 
concentration, different sizes of GNPs including 30, 50, 70 
and 100 nm were defined within the tumor and the absorbed 
dose by the GNPs-loaded tumor were calculated for different 
sizes. Similarly, the absorbed dose was calculated for 
different concentrations of 7, 10, 18 and 30 (mg Au/ gram of 
tumor) in a certain size of GNPs. The dose enhancement 
factor which is defined as the ratio of the absorbed dose by 
the tumor in the presence of nanoparticles to the absorbed 
dose by the same organ in the absence of nanoparticles was 
estimated for different concentrations and sizes of GNPs. 
Results and Conclusion: The calculations show results for 
different sizes and concentrations and a comparison is made 
between the two Monte Carlo codes (MCNP and Geant4). In a 
certain diameter of GNPs the higher concentration made 
more increase in absorbed does by the tumor. In a certain 
concentration, higher size of GNPs made higher absorbed 
dose by the tumor. Given the fact that therapeutic 
applications of GNPs in acquiring the proper DEF have 
demanded much attention in recent years, defining the 
proper size and concentration would be considered extremely 
vital for pre-treatment plans. 
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Purpose: Aim of this study was to investigate, practically 
prove contribution, and verify dosimetry possibilities for low-
risk patients (rhTSH stimulation and 1.1 GBq 131I 
administration) undergoing first Radioiodine therapy (RAIT). 
Furthermore, it was intended to verify whether the 
administered activity deliver sufficient dose to thyroid 
remnants so it can be called ”thyreo-ablative”.   
Materials and methods: Siemens Symbia S gamma camera was 
used for quantitative imaging of 131I accumulation in 
remnants of patients thyroid and 131I accumulating nods. 
Vials with known activity of 131I were used to calibrate the 
system. Verification of activity determination was done by 
measuring the vial together with patient for comparison, if 
necessary. All of the patient-volunteers were around 3 
months after thyreoablation due to thyroid carcinoma. As a 
low-risk indicated patients, they were prepared by injections 
of rhTSH during two days before therapy. Weight of the 
accumulating remnants or nods was established using 
ultrasound, if visible or roughly estimated using phantom 
measurements causing serious uncertainties. 
17 patients (15 women, 2 men) participating the study 
undergone up to 6 quantitative imaging by the gamma 
camera during 70 hours after administration. Minimum of the 
gamma camera examination was 4. General time schedule of 
examination was 5, 24, 30, 48, 70 hours after administration. 
  
Results: Absorbed doses within remnants or nodes vary from 
tens of Gy up to several hundred Gy with uncertainty from 
25% up to 100% depending mainly on mass of the remnants 
estimation. For 5 of the patient the administered therapeutic 
activity caused absorbed dose which was considered to be 
rather insufficient in terms of thyreo-elimination (at least for 
one of accumulating remnants). For 4 patients the absorbed 
dose was considered to be particularly thyreo-eliminative. 
Measurements for 5 patients confirmed thyreo-eliminative 
dose and in case of 3 patients no accumulation was detected. 
Consequent follow-up for all patients is being done. 
Conclusions: Though in nearly 30% of all patients absorbed 
dose did not reach 300 Gy in thyroid remnants and 80 Gy in 
nods, due to low-risk staging it is probable that the 
treatment was successful. However, it is necessary to do 
consequent follow up and include all data for annual 
treatment evaluation. Based on the results appropriate grant 
for further investigation will be seek out. 
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Purpose: Particle therapy cancer treatments require a work 
flow that involve several professional figures, working with a 
complex hardware and software set up. Each professional 
role needs access to a considerable set of information in the 
everyday clinical practice. In particular quality assurance 
protocols demand checking a sensible amount of data. 
The drawback is that often required information are 
physically accessible outside the treatment room, being 
distributed on several computer in different places. 
Integrate and display needed information in an organic and 
easily accessible way can speed up the clinical practice, 
reducing potential time loss and providing a better 
continuous quality control. 
Methods: We propose an innovative tool based on Augmented 
Reality (AR). In AR a view of the physical world is augmented 
with computer generated elements. Our AR tool could be 
installed on a modern mobile device, a tablet or a cellphone. 
Users gets information in real-time about any equipment in 
the treatment room simply pointing the device at it. 
The AR client recognizes medical equipment using the device 
camera, then gathers corresponding information from a cloud 
server, where all data stored. 
The access to the data server is secured with different level 
of privileges: a user can visualize and use only predetermined 
kind of relevant information, according to his role. Moreover, 
all information related to the patient and the medical 
environment are hosted in a private cloud, not accessible 
without proper authentication. 
Results: We present a prototype of AR application for particle 
therapy centre that improves and speeds up the whole work 
flow, making the access to information easier and more 
centralized. 
Here we present a three different use cases that illustrate 
the use of our AR application: medical doctor, medical 
physicists and technical engineer. 
Conclusion: Augmented Reality is the perfect candidate to 
help healthcare organizations make their existing processes 
more precise and efficient. Using AR tools, useful information 
can be provided and related in real-time to the specific need 
of the different systematic tasks that are daily checked 
accurately in an advance radiation therapy facility. 
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Sn-117m has unique characteristics that make it ideal for a 
variety of nuclear medicine applications.  The t1/2=14d 
isotope emits a primary 159 keV imaging photon (86%) that is 
easily detectable with any SPECT camera system. The 
accompanying mono-energetic conversion electrons (~140 
keV; 110%) have a therapeutic effect limited to a range of 
~300 μm which also minimizes any shipping and handling 
issues.  Together these characteristics make this theranostic 
